aluates Reports

$ 0.0

Automative

Recombinant Hepatitis B Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: December 2024

Report Code: QYRE-Auto-11H7978

Global Recombinant Hepatitis B Vaccine Market Insights and Forecast to 2028

BUY CHAPTERS

Recombinant Hepatitis B Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Q: Who are the main players in the Recombinant Hepatitis B Vaccine - Market report?

The main players in the Recombinant Hepatitis B Vaccine - Market are Merck, GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India, Johnson & Johnson, Hualan Biological Engineering, NCPC, China National Biotec Group, Dalian Hissen Bio-pharm, Beijing Tiantan Biological

Q: What are the Application segmentation covered in the Recombinant Hepatitis B Vaccine - Market report?

The Applications covered in the Recombinant Hepatitis B Vaccine - Market report are Newborn, Primary School Students, Adult

Q: What are the Type segmentation covered in the Recombinant Hepatitis B Vaccine - Market report?

The Types covered in the Recombinant Hepatitis B Vaccine - Market report are 10mcg/ml, 10mcg/0.5ml

Code: QYRE-Auto-11H7978

Report

December 2024

Pages:116

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Emergent Biosolutions

Serum Institute of India

Johnson & Johnson

Hualan Biological Engineering

NCPC

China National Biotec Group

Dalian Hissen Bio-pharm

Beijing Tiantan Biological

Recombinant Hepatitis B Vaccine - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Recombinant Hepatitis B Vaccine - Market

The hepatitis b vaccine is a vaccine against hepatitis b.That is, from hepatitis b virus carrier plasma isolation of hepatitis b surface antigen (HbsAg), after treatment and made.After second liver vaccine is inoculated, can stimulate immune system to produce protective antibody, this kind of antibody is in the humoral in the person, once second liver virus appears, antibody can act immediately, clear its, prevent infection, won't harm liver, make human body had the immunity that prevents second liver thereby.Therefore, hepatitis b vaccine has become an indispensable umbrella in life.Prevention generally lasts for at least 12 years, so there is no need for anti-hbs surveillance or enhanced immunity in the general population.However, anti-hbs surveillance can be carried out on high-risk groups, such as anti-hbs <10mIU/ml, which can be given enhanced immunity.

The global market for Recombinant Hepatitis B Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Recombinant Hepatitis B Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Recombinant Hepatitis B Vaccine by region & country, by Type, and by Application.

The Recombinant Hepatitis B Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Hepatitis B Vaccine.

Market Segmentation

Scope of Recombinant Hepatitis B Vaccine - Market Report

Report Metric	Details
Report Name	Recombinant Hepatitis B Vaccine - Market
CAGR	5%
Segment by Type:	10mcg/ml 10mcg/0.5ml
Segment by Application	Newborn Primary School Students Adult
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merck, GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India, Johnson & Johnson, Hualan Biological Engineering, NCPC, China National Biotec Group, Dalian Hissen Bio-pharm, Beijing Tiantan Biological
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant Hepatitis B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Recombinant Hepatitis B Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Recombinant Hepatitis B Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Recombinant Hepatitis B Vaccine - Market report?

Ans: The main players in the Recombinant Hepatitis B Vaccine - Market are Merck, GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India, Johnson & Johnson, Hualan Biological Engineering, NCPC, China National Biotec Group, Dalian Hissen Bio-pharm, Beijing Tiantan Biological

What are the Application segmentation covered in the Recombinant Hepatitis B Vaccine - Market report?

Ans: The Applications covered in the Recombinant Hepatitis B Vaccine - Market report are Newborn, Primary School Students, Adult

What are the Type segmentation covered in the Recombinant Hepatitis B Vaccine - Market report?

Ans: The Types covered in the Recombinant Hepatitis B Vaccine - Market report are 10mcg/ml, 10mcg/0.5ml

1 Market Overview

1.1 Recombinant Hepatitis B Vaccine Product Introduction

1.2 Global Recombinant Hepatitis B Vaccine Market Size Forecast

1.2.1 Global Recombinant Hepatitis B Vaccine Sales Value (2019-2030)

1.2.2 Global Recombinant Hepatitis B Vaccine Sales Volume (2019-2030)

1.2.3 Global Recombinant Hepatitis B Vaccine Sales Price (2019-2030)

1.3 Recombinant Hepatitis B Vaccine Market Trends & Drivers

1.3.1 Recombinant Hepatitis B Vaccine Industry Trends

1.3.2 Recombinant Hepatitis B Vaccine Market Drivers & Opportunity

1.3.3 Recombinant Hepatitis B Vaccine Market Challenges

1.3.4 Recombinant Hepatitis B Vaccine Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Recombinant Hepatitis B Vaccine Players Revenue Ranking (2023)

2.2 Global Recombinant Hepatitis B Vaccine Revenue by Company (2019-2024)

2.3 Global Recombinant Hepatitis B Vaccine Players Sales Volume Ranking (2023)

2.4 Global Recombinant Hepatitis B Vaccine Sales Volume by Company Players (2019-2024)

2.5 Global Recombinant Hepatitis B Vaccine Average Price by Company (2019-2024)

2.6 Key Manufacturers Recombinant Hepatitis B Vaccine Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Recombinant Hepatitis B Vaccine Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Recombinant Hepatitis B Vaccine

2.9 Recombinant Hepatitis B Vaccine Market Competitive Analysis

2.9.1 Recombinant Hepatitis B Vaccine Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Recombinant Hepatitis B Vaccine Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Hepatitis B Vaccine as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 10mcg/ml

3.1.2 10mcg/0.5ml

3.2 Global Recombinant Hepatitis B Vaccine Sales Value by Type

3.2.1 Global Recombinant Hepatitis B Vaccine Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Recombinant Hepatitis B Vaccine Sales Value, by Type (2019-2030)

3.2.3 Global Recombinant Hepatitis B Vaccine Sales Value, by Type (%) (2019-2030)

3.3 Global Recombinant Hepatitis B Vaccine Sales Volume by Type

3.3.1 Global Recombinant Hepatitis B Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Recombinant Hepatitis B Vaccine Sales Volume, by Type (2019-2030)

3.3.3 Global Recombinant Hepatitis B Vaccine Sales Volume, by Type (%) (2019-2030)

3.4 Global Recombinant Hepatitis B Vaccine Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Newborn

4.1.2 Primary School Students

4.1.3 Adult

4.2 Global Recombinant Hepatitis B Vaccine Sales Value by Application

4.2.1 Global Recombinant Hepatitis B Vaccine Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Recombinant Hepatitis B Vaccine Sales Value, by Application (2019-2030)

4.2.3 Global Recombinant Hepatitis B Vaccine Sales Value, by Application (%) (2019-2030)

4.3 Global Recombinant Hepatitis B Vaccine Sales Volume by Application

4.3.1 Global Recombinant Hepatitis B Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Recombinant Hepatitis B Vaccine Sales Volume, by Application (2019-2030)

4.3.3 Global Recombinant Hepatitis B Vaccine Sales Volume, by Application (%) (2019-2030)

4.4 Global Recombinant Hepatitis B Vaccine Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Recombinant Hepatitis B Vaccine Sales Value by Region

5.1.1 Global Recombinant Hepatitis B Vaccine Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Recombinant Hepatitis B Vaccine Sales Value by Region (2019-2024)

5.1.3 Global Recombinant Hepatitis B Vaccine Sales Value by Region (2025-2030)

5.1.4 Global Recombinant Hepatitis B Vaccine Sales Value by Region (%), (2019-2030)

5.2 Global Recombinant Hepatitis B Vaccine Sales Volume by Region

5.2.1 Global Recombinant Hepatitis B Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Recombinant Hepatitis B Vaccine Sales Volume by Region (2019-2024)

5.2.3 Global Recombinant Hepatitis B Vaccine Sales Volume by Region (2025-2030)

5.2.4 Global Recombinant Hepatitis B Vaccine Sales Volume by Region (%), (2019-2030)

5.3 Global Recombinant Hepatitis B Vaccine Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

5.4.2 North America Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

5.5.2 Europe Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

5.6.2 Asia Pacific Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

5.7.2 South America Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

5.8.2 Middle East & Africa Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Value

6.2.1 Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

6.2.2 Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

6.3.2 United States Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Recombinant Hepatitis B Vaccine Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

6.4.2 Europe Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Recombinant Hepatitis B Vaccine Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

6.5.2 China Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

6.5.3 China Recombinant Hepatitis B Vaccine Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

6.6.2 Japan Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Recombinant Hepatitis B Vaccine Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

6.7.2 South Korea Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Recombinant Hepatitis B Vaccine Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

6.8.2 Southeast Asia Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Recombinant Hepatitis B Vaccine Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Recombinant Hepatitis B Vaccine Sales Value, 2019-2030

6.9.2 India Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

6.9.3 India Recombinant Hepatitis B Vaccine Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Merck

7.1.1 Merck Company Information

7.1.2 Merck Introduction and Business Overview

7.1.3 Merck Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Merck Recombinant Hepatitis B Vaccine Product Offerings

7.1.5 Merck Recent Development

7.2 GlaxoSmithKline Plc

7.2.1 GlaxoSmithKline Plc Company Information

7.2.2 GlaxoSmithKline Plc Introduction and Business Overview

7.2.3 GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.2.4 GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Product Offerings

7.2.5 GlaxoSmithKline Plc Recent Development

7.3 Pfizer Inc.

7.3.1 Pfizer Inc. Company Information

7.3.2 Pfizer Inc. Introduction and Business Overview

7.3.3 Pfizer Inc. Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Pfizer Inc. Recombinant Hepatitis B Vaccine Product Offerings

7.3.5 Pfizer Inc. Recent Development

7.4 Sanofi Pasteur

7.4.1 Sanofi Pasteur Company Information

7.4.2 Sanofi Pasteur Introduction and Business Overview

7.4.3 Sanofi Pasteur Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Sanofi Pasteur Recombinant Hepatitis B Vaccine Product Offerings

7.4.5 Sanofi Pasteur Recent Development

7.5 CSL Limited

7.5.1 CSL Limited Company Information

7.5.2 CSL Limited Introduction and Business Overview

7.5.3 CSL Limited Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.5.4 CSL Limited Recombinant Hepatitis B Vaccine Product Offerings

7.5.5 CSL Limited Recent Development

7.6 Emergent Biosolutions

7.6.1 Emergent Biosolutions Company Information

7.6.2 Emergent Biosolutions Introduction and Business Overview

7.6.3 Emergent Biosolutions Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Emergent Biosolutions Recombinant Hepatitis B Vaccine Product Offerings

7.6.5 Emergent Biosolutions Recent Development

7.7 Serum Institute of India

7.7.1 Serum Institute of India Company Information

7.7.2 Serum Institute of India Introduction and Business Overview

7.7.3 Serum Institute of India Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Serum Institute of India Recombinant Hepatitis B Vaccine Product Offerings

7.7.5 Serum Institute of India Recent Development

7.8 Johnson & Johnson

7.8.1 Johnson & Johnson Company Information

7.8.2 Johnson & Johnson Introduction and Business Overview

7.8.3 Johnson & Johnson Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Johnson & Johnson Recombinant Hepatitis B Vaccine Product Offerings

7.8.5 Johnson & Johnson Recent Development

7.9 Hualan Biological Engineering

7.9.1 Hualan Biological Engineering Company Information

7.9.2 Hualan Biological Engineering Introduction and Business Overview

7.9.3 Hualan Biological Engineering Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Hualan Biological Engineering Recombinant Hepatitis B Vaccine Product Offerings

7.9.5 Hualan Biological Engineering Recent Development

7.10 NCPC

7.10.1 NCPC Company Information

7.10.2 NCPC Introduction and Business Overview

7.10.3 NCPC Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.10.4 NCPC Recombinant Hepatitis B Vaccine Product Offerings

7.10.5 NCPC Recent Development

7.11 China National Biotec Group

7.11.1 China National Biotec Group Company Information

7.11.2 China National Biotec Group Introduction and Business Overview

7.11.3 China National Biotec Group Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.11.4 China National Biotec Group Recombinant Hepatitis B Vaccine Product Offerings

7.11.5 China National Biotec Group Recent Development

7.12 Dalian Hissen Bio-pharm

7.12.1 Dalian Hissen Bio-pharm Company Information

7.12.2 Dalian Hissen Bio-pharm Introduction and Business Overview

7.12.3 Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.12.4 Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Product Offerings

7.12.5 Dalian Hissen Bio-pharm Recent Development

7.13 Beijing Tiantan Biological

7.13.1 Beijing Tiantan Biological Company Information

7.13.2 Beijing Tiantan Biological Introduction and Business Overview

7.13.3 Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.13.4 Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Product Offerings

7.13.5 Beijing Tiantan Biological Recent Development

8 Industry Chain Analysis

8.1 Recombinant Hepatitis B Vaccine Industrial Chain

8.2 Recombinant Hepatitis B Vaccine Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Recombinant Hepatitis B Vaccine Sales Model

8.5.2 Sales Channel

8.5.3 Recombinant Hepatitis B Vaccine Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Emergent Biosolutions

Serum Institute of India

Johnson & Johnson

Hualan Biological Engineering

NCPC

China National Biotec Group

Dalian Hissen Bio-pharm

Beijing Tiantan Biological

List of Tables

Table 1. Recombinant Hepatitis B Vaccine Market Trends

Table 2. Recombinant Hepatitis B Vaccine Market Drivers & Opportunity

Table 3. Recombinant Hepatitis B Vaccine Market Challenges

Table 4. Recombinant Hepatitis B Vaccine Market Restraints

Table 5. Global Recombinant Hepatitis B Vaccine Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Company (2019-2024)

Table 7. Global Recombinant Hepatitis B Vaccine Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Recombinant Hepatitis B Vaccine Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Recombinant Hepatitis B Vaccine Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Recombinant Hepatitis B Vaccine Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Recombinant Hepatitis B Vaccine Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Recombinant Hepatitis B Vaccine

Table 13. Global Recombinant Hepatitis B Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Hepatitis B Vaccine as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Recombinant Hepatitis B Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Recombinant Hepatitis B Vaccine Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Recombinant Hepatitis B Vaccine Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Recombinant Hepatitis B Vaccine Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Recombinant Hepatitis B Vaccine Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Recombinant Hepatitis B Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Recombinant Hepatitis B Vaccine Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Recombinant Hepatitis B Vaccine Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Recombinant Hepatitis B Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Recombinant Hepatitis B Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Recombinant Hepatitis B Vaccine Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Recombinant Hepatitis B Vaccine Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Recombinant Hepatitis B Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Recombinant Hepatitis B Vaccine Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Recombinant Hepatitis B Vaccine Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Recombinant Hepatitis B Vaccine Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Recombinant Hepatitis B Vaccine Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Recombinant Hepatitis B Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Recombinant Hepatitis B Vaccine Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Recombinant Hepatitis B Vaccine Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Recombinant Hepatitis B Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Recombinant Hepatitis B Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Recombinant Hepatitis B Vaccine Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Recombinant Hepatitis B Vaccine Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Recombinant Hepatitis B Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Recombinant Hepatitis B Vaccine Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Recombinant Hepatitis B Vaccine Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Recombinant Hepatitis B Vaccine Sales Value by Region (2019-2024) & (%)

Table 44. Global Recombinant Hepatitis B Vaccine Sales Value by Region (2025-2030) & (%)

Table 45. Global Recombinant Hepatitis B Vaccine Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Recombinant Hepatitis B Vaccine Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Recombinant Hepatitis B Vaccine Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Recombinant Hepatitis B Vaccine Sales Volume by Region (2019-2024) & (%)

Table 49. Global Recombinant Hepatitis B Vaccine Sales Volume by Region (2025-2030) & (%)

Table 50. Global Recombinant Hepatitis B Vaccine Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Recombinant Hepatitis B Vaccine Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Volume, (2025-2030) & (K Units)

Table 57. Merck Company Information

Table 58. Merck Introduction and Business Overview

Table 59. Merck Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Merck Recombinant Hepatitis B Vaccine Product Offerings

Table 61. Merck Recent Development

Table 62. GlaxoSmithKline Plc Company Information

Table 63. GlaxoSmithKline Plc Introduction and Business Overview

Table 64. GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Product Offerings

Table 66. GlaxoSmithKline Plc Recent Development

Table 67. Pfizer Inc. Company Information

Table 68. Pfizer Inc. Introduction and Business Overview

Table 69. Pfizer Inc. Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Pfizer Inc. Recombinant Hepatitis B Vaccine Product Offerings

Table 71. Pfizer Inc. Recent Development

Table 72. Sanofi Pasteur Company Information

Table 73. Sanofi Pasteur Introduction and Business Overview

Table 74. Sanofi Pasteur Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Sanofi Pasteur Recombinant Hepatitis B Vaccine Product Offerings

Table 76. Sanofi Pasteur Recent Development

Table 77. CSL Limited Company Information

Table 78. CSL Limited Introduction and Business Overview

Table 79. CSL Limited Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. CSL Limited Recombinant Hepatitis B Vaccine Product Offerings

Table 81. CSL Limited Recent Development

Table 82. Emergent Biosolutions Company Information

Table 83. Emergent Biosolutions Introduction and Business Overview

Table 84. Emergent Biosolutions Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Emergent Biosolutions Recombinant Hepatitis B Vaccine Product Offerings

Table 86. Emergent Biosolutions Recent Development

Table 87. Serum Institute of India Company Information

Table 88. Serum Institute of India Introduction and Business Overview

Table 89. Serum Institute of India Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Serum Institute of India Recombinant Hepatitis B Vaccine Product Offerings

Table 91. Serum Institute of India Recent Development

Table 92. Johnson & Johnson Company Information

Table 93. Johnson & Johnson Introduction and Business Overview

Table 94. Johnson & Johnson Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Johnson & Johnson Recombinant Hepatitis B Vaccine Product Offerings

Table 96. Johnson & Johnson Recent Development

Table 97. Hualan Biological Engineering Company Information

Table 98. Hualan Biological Engineering Introduction and Business Overview

Table 99. Hualan Biological Engineering Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. Hualan Biological Engineering Recombinant Hepatitis B Vaccine Product Offerings

Table 101. Hualan Biological Engineering Recent Development

Table 102. NCPC Company Information

Table 103. NCPC Introduction and Business Overview

Table 104. NCPC Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. NCPC Recombinant Hepatitis B Vaccine Product Offerings

Table 106. NCPC Recent Development

Table 107. China National Biotec Group Company Information

Table 108. China National Biotec Group Introduction and Business Overview

Table 109. China National Biotec Group Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. China National Biotec Group Recombinant Hepatitis B Vaccine Product Offerings

Table 111. China National Biotec Group Recent Development

Table 112. Dalian Hissen Bio-pharm Company Information

Table 113. Dalian Hissen Bio-pharm Introduction and Business Overview

Table 114. Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 115. Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Product Offerings

Table 116. Dalian Hissen Bio-pharm Recent Development

Table 117. Beijing Tiantan Biological Company Information

Table 118. Beijing Tiantan Biological Introduction and Business Overview

Table 119. Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 120. Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Product Offerings

Table 121. Beijing Tiantan Biological Recent Development

Table 122. Key Raw Materials Lists

Table 123. Raw Materials Key Suppliers Lists

Table 124. Recombinant Hepatitis B Vaccine Downstream Customers

Table 125. Recombinant Hepatitis B Vaccine Distributors List

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

List of Figures

Figure 1. Recombinant Hepatitis B Vaccine Product Picture

Figure 2. Global Recombinant Hepatitis B Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Recombinant Hepatitis B Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Recombinant Hepatitis B Vaccine Sales Volume (2019-2030) & (K Units)

Figure 5. Global Recombinant Hepatitis B Vaccine Sales Price (2019-2030) & (US$/Unit)

Figure 6. Recombinant Hepatitis B Vaccine Report Years Considered

Figure 7. Global Recombinant Hepatitis B Vaccine Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Recombinant Hepatitis B Vaccine Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Recombinant Hepatitis B Vaccine Revenue in 2023

Figure 10. Recombinant Hepatitis B Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. 10mcg/ml Picture

Figure 12. 10mcg/0.5ml Picture

Figure 13. Global Recombinant Hepatitis B Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Recombinant Hepatitis B Vaccine Sales Value Market Share by Type, 2023 & 2030

Figure 15. Global Recombinant Hepatitis B Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 16. Global Recombinant Hepatitis B Vaccine Sales Volume Market Share by Type, 2023 & 2030

Figure 17. Global Recombinant Hepatitis B Vaccine Price by Type (2019-2030) & (US$/Unit)

Figure 18. Product Picture of Newborn

Figure 19. Product Picture of Primary School Students

Figure 20. Product Picture of Adult

Figure 21. Global Recombinant Hepatitis B Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 22. Global Recombinant Hepatitis B Vaccine Sales Value Market Share by Application, 2023 & 2030

Figure 23. Global Recombinant Hepatitis B Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 24. Global Recombinant Hepatitis B Vaccine Sales Volume Market Share by Application, 2023 & 2030

Figure 25. Global Recombinant Hepatitis B Vaccine Price by Application (2019-2030) & (US$/Unit)

Figure 26. North America Recombinant Hepatitis B Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 27. North America Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 28. Europe Recombinant Hepatitis B Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 29. Europe Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 30. Asia Pacific Recombinant Hepatitis B Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 32. South America Recombinant Hepatitis B Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 33. South America Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 34. Middle East & Africa Recombinant Hepatitis B Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 35. Middle East & Africa Recombinant Hepatitis B Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 36. Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Value (%), (2019-2030)

Figure 37. Key Countries/Regions Recombinant Hepatitis B Vaccine Sales Volume (%), (2019-2030)

Figure 38. United States Recombinant Hepatitis B Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 39. United States Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 40. United States Recombinant Hepatitis B Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 41. Europe Recombinant Hepatitis B Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 42. Europe Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 43. Europe Recombinant Hepatitis B Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 44. China Recombinant Hepatitis B Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 45. China Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 46. China Recombinant Hepatitis B Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 47. Japan Recombinant Hepatitis B Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 48. Japan Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 49. Japan Recombinant Hepatitis B Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 50. South Korea Recombinant Hepatitis B Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 51. South Korea Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 52. South Korea Recombinant Hepatitis B Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 53. Southeast Asia Recombinant Hepatitis B Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 54. Southeast Asia Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 55. Southeast Asia Recombinant Hepatitis B Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 56. India Recombinant Hepatitis B Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 57. India Recombinant Hepatitis B Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 58. India Recombinant Hepatitis B Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 59. Recombinant Hepatitis B Vaccine Industrial Chain

Figure 60. Recombinant Hepatitis B Vaccine Manufacturing Cost Structure

Figure 61. Channels of Distribution (Direct Sales, and Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions